Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity

Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity

<jats:p>Low plasma levels of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) are associated with decreased low-density lipoprotein (LDL) cholesterol and a reduced risk of cardiovascular disease. PCSK9 binds to the epidermal growth factor-like repeat A (EGFA) domain of LDL receptors (LDLR), ve...

Full description

Bibliographic Details
Main Authors: Deshycka, Rhogerry, Sudaryo, Valentino, Huang, Nai-Jia, Xie, Yushu, Smeding, Liyan Y, Choi, Moon Kyung, Ploegh, Hidde L, Lodish, Harvey F, Pishesha, Novalia
Other Authors: Massachusetts Institute of Technology. Department of Biology
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022
Online Access:https://hdl.handle.net/1721.1/146897

Internet

https://hdl.handle.net/1721.1/146897

Similar Items